Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-382-0 | CAS number: 941-69-5
Endpoint summary
Administrative data
Description of key information
The NOAEL for oral is 3.5 mg/kg/day.
The NOAEL for inhalation is 0.21 mg/m3.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 3.5 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEC
- 0.21 mg/m³
- Study duration:
- subacute
- Species:
- rat
Additional information
Oral:
In a subchronic toxicity study the substance was administered to SPF SD rats four weeks/male and female/dose in suspended 5 (w/v) % arabic gum water solution, by gavag eat dose levels of 0, 3.5, 11.0 & 35.0 mg/kg bw/day.
The substance induced toxic changes due to irritation.
The NOAEL is 3.5 mg/kg/day based on irritative property in Rats by the 30 days oral administration.
In a screening study by OECD 422, this study's result shows irritative property of this substance causes local effects but absence of systemic effects. On the view point of the endpoint on repeat toxicity consideration, male' adverse effect during 51 days exposure is effective but female's adverse effect during this exposure period is not reliable due to maternal toxicity in this combined repeat dose and reproductive/developmental toxicity screening study.
The NOEL and LOAEL for oral repeat dose in male is 2.5 mg/kg/day by using OECD 422 test method.
Inhalation:
The NOAEL is 0.21 mg/m3 based on 28 -day inhalation study in rats.
The commercial product (>355 um) has practically no micronized particle size (<10 um).
However, one should consider the DNEL for inhalation for workers because of any accidental release of this product at polymer manufacturers plant site.
Regarding dermal consideration, low predicted levels of dermal exposure to humans as shown in the chemical safety assessment, physicochemical properties indicating low potential for dermal penetration (log Pow 1.16) and absence of systemic toxicity in skin irritation, eye irritation and sensitisation studies.
This subchronic toxicity endpoint is waived based on REACH annex IX Section 8.6.2 column 2 on grounds that two reliable repeat dose studies are available by the oral route one of which is shows an extended ca 50 days of exposure for male. These clearly identify that the only significant effects seen are related to the irritant nature of this substance, therefore there are no other findings of toxicological significance.
Justification for classification or non-classification
Repeat toxicity-irreversible damage after repeat exposure: non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
